NCT06074497 2025-02-07
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.
Kangabio AUSTRALIA LTD PTY
Phase 1 Active not recruiting